What Reviva Pharmaceuticals does

Reviva Pharmaceuticals Holdings, Inc. is a late-stage clinical pharmaceutical company headquartered in Cupertino, California, focused on discovering and developing novel therapies for central nervous system (CNS), respiratory, and metabolic diseases with significant unmet medical needs. Founded in 2006 by Dr. Laxminarayan Bhat, the company uses a proprietary chemical genomics-driven technology platform to discover new chemical entities, with its lead candidate brilaroxazine (RP5063) acting as a serotonin/dopamine modulator in Phase 3 development for schizophrenia (primary), bipolar disorder, major depressive disorder, ADHD, and psychotic symptoms in Alzheimer's and Parkinson's disease. A second candidate, RP1208, is a triple reuptake inhibitor in earlier-stage development for depression and obesity, and the company has also pursued indications in pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and psoriasis via topical formulation.

The company's clinical foundation includes more than 900 subjects treated across Phase 2 and Phase 3 trials, with the pivotal RECOVER trial having met primary and secondary endpoints; however, FDA feedback received in late 2025 requires an additional Phase 3 trial (RECOVER-2) before NDA submission. Reviva's intellectual property portfolio includes composition of matter patents granted in the US, Europe, and multiple other jurisdictions, with a provisional filing aimed at extending brilaroxazine exclusivity through 2046. The company has also developed a vocal biomarker enrichment technology for clinical trial patient stratification, published in Biological Psychiatry.

Reviva is pre-revenue with no approved commercial products, generates no product sales, and relies on equity financings to fund operations. As of March 31, 2026, cash stood at $22.2 million against a FY2025 net loss of $19.9 million and a Q1 2026 net loss of $3.2 million (improved from $6.4 million in Q1 2025). The company has raised approximately $70 million in post-IPO equity offerings between 2022 and 2026 and has a $50 million at-the-market facility available. In March 2026, Reviva executed a 1-for-20 reverse stock split and in May 2026 transitioned from Nasdaq to the OTCQB Venture Market. The go-to-market strategy upon approval is expected to use traditional pharmaceutical channels including specialty pharmacies, healthcare providers, and potentially partnerships with larger pharmaceutical companies for commercialization.

Name

Reviva Pharmaceuticals

Legal name

Reviva Pharmaceuticals Holdings, Inc.

Website

https://revivapharma.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Reviva Pharmaceuticals is a late-stage clinical pharmaceutical company developing novel therapies for CNS, respiratory, and metabolic diseases, with lead candidate brilaroxazine in Phase 3 development for schizophrenia and a second candidate, RP1208, in preclinical development for depression and obesity.

Ownership category

akta.pro rank

Product category

Clinical-stage neuropsychiatric pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Clinical-stage pharmaceuticals
• Neuropsychiatric drug development
• Schizophrenia therapeutics
• CNS disorder treatments
• New chemical entities

Headquarters

HQ city

Cupertino

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Once FDA approval is obtained, the company plans to commercialize brilaroxazine and other drug candidates through prescription drug sales via healthcare providers and pharmacies.

Go-to-market motion1 record

Marketing channels6 records

Core offering

Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company developing two internally discovered new chemical entity drug candidates. Lead candidate brilaroxazine (RP5063) is a serotonin/dopamine modulator in Phase 3 development for schizophrenia and multiple neuropsychiatric indications, while RP1208 is a triple reuptake inhibitor in preclinical development for depression and metabolic conditions. Both candidates were discovered using the company's proprietary chemical genomics-driven technology platform.

Product overview

Reviva Pharmaceuticals is a clinical-stage pharmaceutical company with two internally discovered new chemical entity (NCE) drug candidates. The company's lead product is brilaroxazine (RP5063), a serotonin/dopamine modulator being developed for multiple neuropsychiatric indications with schizophrenia as the primary focus. The second candidate, RP1208, is a triple reuptake inhibitor in earlier development for depression and other conditions. Both compounds were discovered using the company's proprietary chemical genomics-driven technology platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Brilaroxazine (RP5063) Brilaroxazine (RP5063) is a new chemical entity serotonin/dopamine modulator that displays partial agonist activity for D2/3/4 and 5-HT1A/2A, antagonist activity for 5-HT2B/2C/7, and moderate affinity for the serotonin transporter. It is being developed for adult patients with schizophrenia and other neuropsychiatric indications, demonstrating broad-spectrum efficacy across positive, negative, and mood symptoms with anti-inflammatory effects and a favorable metabolic and safety profile.
• RP1208 RP1208 is a new chemical entity triple reuptake inhibitor in preclinical development for potential treatment of depression, obesity, and other metabolic indications. It was discovered in-house using Reviva's chemical genomics-driven technology platform and is covered by composition of matter patents granted in the US, Europe, and multiple other countries.

Quantifiable outcome

• Statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg brilaroxazine vs placebo in Phase 3 RECOVER trial
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vanda Pharmaceuticals: Specialty CNS pharmaceutical company with approved products (Fanapt for schizophrenia, Hetlioz) and a pipeline focused on neuropsychiatric disorders. Comparable as a small/mid-cap CNS specialty pharma with schizophrenia commercial exposure.
• Intra-Cellular Therapies: Developed Caplyta (lumateperone), approved for schizophrenia and bipolar depression, and was acquired by AbbVie in 2025. Direct head-to-head competitor in the schizophrenia space with a successfully commercialized CNS asset.
• Axsome Therapeutics: Late-stage CNS pharmaceutical company with Auvelity approved for major depressive disorder and additional CNS programs. Comparable as a small-cap, late-stage CNS company targeting multiple neuropsychiatric indications with novel mechanisms.
• Karuna Therapeutics: Developed Cobenfy (xanomeline/trospium), approved for schizophrenia, and was acquired by Bristol-Myers Squibb in 2024. Closest direct peer in mechanism (muscarinic/dopaminergic modulation), indication (schizophrenia), and clinical-stage trajectory.
• BioXcel Therapeutics: CNS-focused specialty pharmaceutical company with an approved drug (Igalmi) for agitation in schizophrenia/bipolar and a clinical pipeline in CNS. Similar small-cap, CNS-pure-play commercial-stage profile.
• Acadia Pharmaceuticals: Specialty CNS pharmaceutical company with an approved drug (Nuplazid) for Parkinson's disease psychosis. Highly comparable late-stage CNS focus, novel-mechanism antipsychotic strategy, and schizophrenia-adjacent label expansion ambitions overlap directly with Reviva's lead asset positioning.
• Sage Therapeutics: CNS-focused pharmaceutical company that developed Zurzuvae for postpartum depression and was acquired by Biogen. Comparable as a clinical-stage-to-commercial CNS company pursuing neuropsychiatric indications with novel mechanisms.
• Neumora Therapeutics: Clinical-stage neuroscience company developing therapies for brain diseases including schizophrenia and other CNS indications. Closely comparable as a small-cap, CNS-pure-play, clinical-stage biopharma at a similar stage of development to Reviva.

Emerging players

• COMPASS Pathways: Clinical-stage mental-health company developing psilocybin therapy for treatment-resistant depression. Comparable as a clinical-stage CNS-focused biopharma pursuing neuropsychiatric indications with a novel mechanism, although at an earlier commercial stage.
• Cybin: Smaller clinical-stage CNS company developing psychedelic-based therapies for psychiatric conditions including depression. Comparable as an emerging CNS-focused clinical-stage company targeting neuropsychiatric indications, though with a different therapeutic modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/RevivaPharma
• YouTubeyoutube.com/@RevivaPharmaceuticals
• LinkedInlinkedin.com/company/reviva-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds13 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reviva Pharmaceuticals